April 25, 2017 1:12 PM ET

Pharmaceuticals

Company Overview of Heptares Therapeutics Ltd.

Company Overview

Heptares Therapeutics Ltd., a clinical-stage company, creates novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a range of human diseases. It offers GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, NCE discovery, and antibody discovery. Heptares Therapeutics Ltd. has a strategic agreement with Pfizer Inc.; and strategic collaboration with Kymab Limited and Jitsubo Co., Ltd. The company was founded in 2007 and is based in Welwyn Garden City, United Kingdom. As of February 22, 2015, Heptares Therapeutics Ltd. operates as a subsidiary of Sosei Group Corporation.

BioPark

Broadwater Road

Welwyn Garden City,  AL7 3AX

United Kingdom

Founded in 2007

Phone:

44 17 0735 8628

Fax:

44 17 0735 8640

Key Executives for Heptares Therapeutics Ltd.

Founder, Chairman and Chief Executive Officer
Age: 58
Founder, Chief Scientific Officer and Director
Age: 52
President of USA Operations
Age: 49
Chief Medical Officer and Vice President of Development
Age: 63
Chief Business Officer
Compensation as of Fiscal Year 2016.

Heptares Therapeutics Ltd. Key Developments

Heptares Therapeutics Ltd. to Receive $12 Million Milestone Payment from Astrazeneca

Sosei Group Corporation reported that its subsidiary, Heptares Therapeutics has announced that it has achieved an important milestone in its immuno-oncology collaboration with AstraZeneca, which is focused on the development of AZD4635 (HTL-1071) as a potential new treatment for a range of cancers. As a result, Heptares has been notified that the achievement has triggered a $12 million payment from AstraZeneca. AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor antagonist discovered by Heptares and licensed to AstraZeneca in 2015.

Daiichi Sankyo Signs Development Contract with Heptares Therapeutics

Daiichi Sankyo has signed a contract with United Kingdom-based Heptares Therapeutics. It was reported that the agreement has been signed to discover and develop small-molecules for the treatment of pain. The firms will concentrate on a single G protein-coupled receptor nominated by Daiichi Sankyo, which plays a crucial role in relieving pain. Heptares will implement its proprietary StaR (stabilised receptor) technology to engineer thermally stabilised forms of the G protein-coupled receptor as the basis for the drug discovery programme. Heptares will also employ advanced structural biology and rational drug design approaches, X-ray crystallography and fragment screening to delineate the G protein-coupled receptor's structure and to generate lead candidates. Daiichi Sankyo will also participate in lead generation and in vivo models. It will be eligible to receive global rights to develop, manufacture and commercialise novel, small molecules discovered by Heptares concentrated on the nominated G protein-coupled receptor. In return, Heptares will receive an upfront payment, research funding, and is eligible to receive additional research, development and commercialisation milestone payments. Heptares will also be eligible to receive royalties on net sales of products resulting from the alliance.

Heptares Therapeutics Enters Agreement with Daiichi Sankyo to Discover and Develop Novel, Small-Molecules for the Treatment of Pain

Heptares Therapeutics announced that it has entered into a drug discovery and licensing agreement with Daiichi Sankyo Company, Limited focused on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain. Under the terms of the agreement, Daiichi Sankyo will receive exclusive global rights to develop, manufacture and commercialize novel, small molecules discovered by Heptares focused on the nominated GPCR. In return, Heptares will receive an upfront payment of $4 million, research funding of approximately $8 million, and is eligible to receive additional research, development and commercialization milestone payments. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.

Similar Private Companies By Industry

Company Name Region
Abbey Pharma Limited Europe
Absynth Biologics Limited Europe
Acacia Pharma Limited Europe
AccentBio Ltd. Europe
Aclar Limited Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 30, 2016
G7 Therapeutics AG
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Heptares Therapeutics Ltd., please visit www.heptares.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.